Scott Van Wier
Mayo Clinic in Arizona · 92 works · 3,626 citations · h-index 16
Top works
- Promiscuous Mutations Activate the Noncanonical NF-κB Pathway in Multiple Myeloma
- Clonal competition with alternating dominance in multiple myeloma
- Cereblon expression is required for the antimyeloma activity of lenalidomide and pomalidomide
- Selective Inhibition of Nuclear Export With Oral Selinexor for Treatment of Relapsed or Refractory Multiple Myeloma
- Genome-Wide Analysis Uncovers Novel Recurrent Alterations in Primary Central Nervous System Lymphomas
- Promiscuous MYC locus rearrangements hijack enhancers but mostly super-enhancers to dysregulate MYC expression in multiple myeloma
- Identification of Copy Number Abnormalities and Inactivating Mutations in Two Negative Regulators of Nuclear Factor-κB Signaling Pathways in Waldenstrom's Macroglobulinemia
- Clinical significance of TP53 mutation in myeloma
- Clinical and biological significance of RAS mutations in multiple myeloma
- Relationship between elevated immunoglobulin free light chain and the presence of IgH translocations in multiple myeloma
- Targeted sequencing using a 47 gene multiple myeloma mutation panel (M3P) in ‐17p high risk disease
- Hypodiploid multiple myeloma is characterized by more aggressive molecular markers than non-hyperdiploid multiple myeloma
- Correlation between array-comparative genomic hybridization-defined genomic gains and losses and survival: identification of 1p31-32 deletion as a prognostic factor in myeloma
- Diagnostic evaluation of t(4;14) in multiple myeloma and evidence for clonal evolution
- High-Resolution Genomic Analysis in Waldenström's Macroglobulinemia Identifies Disease-Specific and Common Abnormalities with Marginal Zone Lymphomas
- Whole Genome Analyses of a Well-Differentiated Liposarcoma Reveals Novel SYT1 and DDR2 Rearrangements
- Low Level Amplification (Duplication) of 1q21 in Myeloma and Prognosis; the Role of CKS1B.
- Loss of p53 Is a Marker of Progression in Plasma Cell Neoplasias and Is a Negative Prognostic Factor in Relapsed Disease.
- Lenalidomide Inhibits Thioredoxin Reductase (TrxR) in Multiple Myeloma (MM) Cells but Direct Inhibition of Trxr and Thioredoxin (Trx) Can Bypass Requirement of Cereblon (CRBN)
- Abstract 219: TP53 loss: An overriding marker of disease progression in Multiple Myeloma